Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

UNC studies target molecular defects implicated in cancer, genetic diseases

09.01.2003


In three separate studies, scientists at the University of North Carolina at Chapel Hill School of Medicine have shown that it is possible to correct defective molecular splicing pathways that would otherwise contribute to cancer, genetic diseases and possibly other disorders.



These corrections were accomplished by the insertion into the cell of antisense oligonucleotides, short strands of genetic material that target portions of RNA. RNA carries the DNA blueprint for cellular protein production in gene expression. The technique for correcting these defective molecular splicing pathways was pioneered by Dr. Ryszard Kole, professor of pharmacology and a member of the UNC Lineberger Comprehensive Cancer Center.

In a new study published Dec. 20 in the Journal of Biological Chemistry, Kole and colleagues used these techniques to eradicate certain cancer cells or to increase their sensitivity to treatment.


While tumors initially respond to radiation or chemotherapy, they frequently become resistant to subsequent treatments. One form of resistance develops when cancer cells no longer respond to signaling molecules that tell the cells to die, a process known as apoptosis. In the new report, RNA splicing of the gene that controls apoptosis was targeted with antisense oligonucleotides.

"RNA splicing is the essential process of cutting and pasting the genetic code into a continuous reading frame to produce protein," said Kole. "The cell can splice each RNA into multiple, alternative forms, which result in related but different proteins. In cancer cells, this process may be modified and contribute to resistance to apoptosis."

For example, RNA coded by a gene, bcl-x, is alternately spliced into two different forms, both of which play an important role in apoptosis. The short form, bcl-xS, promotes apoptosis and cell death, while the long form, bcl-xL, prevents apoptosis and promotes cell growth.

Accordingly, higher levels of bcl-xL have been found in malignant cancers of the prostate and have been correlated with increased resistance of these cancers to chemotherapeutic agents. In the new study, antisense molecules were used to shift the alternative splicing of bcl-x from the anti-apoptotic form to the pro-apoptotic form in cancer cell lines, including cancers of the prostate and breast. In doing so, the UNC researchers were able to sensitize these cell lines to various chemotherapeutic agents and radiation.

"Our gene-based therapy would presumably be specific for cancer cells, which overexpress the anti-apoptotic form of RNA," said Dr. Danielle Mercatante, first author of the study and a postdoctoral fellow at the Lineberger center. "This approach could offer a significant advantage over conventional therapies, which are non-specific and kill both cancerous and non-cancerous cells."

This study used cells in culture. But in a December report in Nature Biotechnology, Kole and colleagues demonstrated they could alter splicing defects in a mouse. In this report, they inserted a gene with a splicing defect into the mouse genome. The gene fluoresces bright green when the splicing defect has been successfully blocked with antisense oligonucleotides. Injection of antisense oligonucleotides into the transgenic mouse model blocked defective splicing, leading to green fluorescence activity in several tissues.

"To my knowledge, our study was the first demonstration that a systemically injected oligonucleotide could shift splicing in vivo," said Peter Sazani, first author of the study and postdoctoral researcher at the Lineberger center.

"The transgenic mouse provides a platform to compare the various oligonucleotide modifications that could lead to improvements in the stability, uptake and binding of the oligonucleotides to the target," said Kole. "These improvements will allow the oligonucleotides to modify splicing in patients in the not-too-distant future."

Besides these two reports, the Kole laboratory last year demonstrated the therapeutic potential of this method in blood from patients with a form of beta-thalassemia, a genetic disease that affects as many as one in 10 of the Mediterranean population. The study showed that antisense molecules could be used to increase the production of hemoglobin, the protein necessary to reduce the patient’s anemia. In September, the findings were published in the online edition of the journal Blood, a publication of the American Society of Hematology. They also appear in the Jan.1 issue of the journal.

"Taken together the three reports show the possibility of wide application of targeting splicing with antisense molecules," said Kole. "In fact, recent findings that a large fraction, if not a majority, of genes are alternatively spliced indicate that this approach may be applicable to hundreds of disorders."

The National Heart, Lung and Blood Institute, a component of the National Institutes of Health, provided funding for the research.

By MARLA M. VACEK UNC School of Medicine



Note: Contact Kole at 919-966-1143 or kole@med.unc.edu. Contact Mercatante at danielle@med.unc.edu. Contact Sazani at sazani@email.unc.edu. School of Medicine contact: Leslie H. Lang, 919-843-9687 or llang@med.unc.edu.




Leslie Lang | EurekAlert!
Further information:
http://www.med.unc.edu/

More articles from Life Sciences:

nachricht Toward a 'smart' patch that automatically delivers insulin when needed
18.01.2017 | American Chemical Society

nachricht 127 at one blow...
18.01.2017 | Stiftung Zoologisches Forschungsmuseum Alexander Koenig, Leibniz-Institut für Biodiversität der Tiere

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

A big nano boost for solar cells

18.01.2017 | Power and Electrical Engineering

Glass's off-kilter harmonies

18.01.2017 | Materials Sciences

Toward a 'smart' patch that automatically delivers insulin when needed

18.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>